 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C13H21N3O |
| Molar mass | 235.331 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
PF-592,379 is a drug developed byPfizer which acts as a potent,selective and orally activeagonist for thedopamineD3receptor, which was under development as a potential medication for the treatment offemale sexual dysfunction and maleerectile dysfunction. Unlike some other less selective D3 agonists, a research study showed that PF-592,379 has little abuse potential in animal studies, and so was selected for further development and potentially human clinical trials.[1][2]Development has since been discontinued.[3]
